Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
72.00
+0.72 (1.01%)
At close: Jun 16, 2025, 4:00 PM
71.01
-0.99 (-1.38%)
After-hours: Jun 16, 2025, 7:59 PM EDT
1.01%
Market Cap 12.46B
Revenue (ttm) 803.32M
Net Income (ttm) -721.31M
Shares Out 173.12M
EPS (ttm) -4.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,201,946
Open 72.15
Previous Close 71.28
Day's Range 71.22 - 74.83
52-Week Range 22.89 - 91.45
Beta n/a
Analysts Buy
Price Target 63.90 (-11.25%)
Earnings Date Aug 5, 2025

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 2,400
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $63.9, which is a decrease of -11.25% from the latest price.

Price Target
$63.9
(-11.25% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025

MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or ...

3 days ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDA...

4 days ago - Accesswire

Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams...

4 days ago - Business Wire

Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDA...

5 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Shareholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDA...

6 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Tempus AI, Inc. (TEM) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

7 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

8 days ago - Accesswire

I'm Still Bullish On Tempus AI

TEM is a data-rich platform that recently clinched a $200 million deal with AstraZeneca. TEM's main bet is now on AI for healthcare applications. I believe TEM's main business moat is its vast and rap...

9 days ago - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

10 days ago - Accesswire

Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

11 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Tempus AI, Inc. (TEM) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

12 days ago - Accesswire

Tempus AI, Inc. (TEM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

14 days ago - Accesswire

Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monit...

14 days ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

15 days ago - Accesswire

Introducing Tempus One in the EHR with Integrated Guidelines

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its...

15 days ago - Business Wire

Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program...

16 days ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Encourages Tempus AI, Inc. (TEM) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

17 days ago - Accesswire

Tempus Announces 10 Abstracts Accepted for Presentation at the 2025 American Society of Clinical Oncology Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that ten abstracts have been ac...

17 days ago - Business Wire

Tempus AI, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

18 days ago - GlobeNewsWire

Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King' (UPDATED)

Editor's note: This story has been updated to include a statement from a Tempus AI spokesperson.

18 days ago - Benzinga

Tempus: Short Seller Attack Brings Golden Opportunity Cathie Wood Was Waiting For

Tempus AI Inc. TEM just got hit with a short seller grenade—and Cathie Wood showed up with a shopping cart.

18 days ago - Benzinga

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Tempus AI, Inc. (TEM) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ...

18 days ago - Accesswire

Tempus AI, Inc. (NASDAQ: TEM) Securities Fraud Investigation; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

OAKLAND, Calif.--(BUSINESS WIRE)---- $TEM #TEM--Gibbs Mura, A Law Group, is investigating potential legal claims on behalf of shareholders with losses in Tempus AI, Inc. (NASDAQ: TEM).

19 days ago - Business Wire

TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm.

19 days ago - Business Wire

Tempus AI stock wasn't worth owning even without the short report: find out why

Tempus AI Inc (NASDAQ: TEM) came crumbling down on Wednesday after Spruce Point announced a short position in the Chicago headquartered health technology company. Spruce Point cited several reasons, i...

19 days ago - Invezz